The administration of Enbrel, a TNFi therapy, to RA patients reverses these levels of regulators towards healthy levels, further supporting the RBP-J/NFATc1-miR-182 regulatory network in controlling TNF-mediated osteoclastogenesis. Here, NFATC1 is linked to rheumatoid arthritis.